Methylprednisolone in Patients With Cognitive Deficits in Post-COVID-19 Syndrome (PCS)
Status:
Recruiting
Trial end date:
2025-03-31
Target enrollment:
Participant gender:
Summary
This clinical trial aims to learn about the therapeutic value of Methylprednisolone, a
well-known immunosuppressant, on cognitive deficits in patients with post-COVID-19 syndrome
(PCS). The main questions it aims to answer are: 1) Does Methylprednisolone improve memory
function in PCS patients compared to placebo? 2) Does Methylprednisolone improve other
patient centered outcomes in PCS patients such as fatigue, mood and quality of life compared
to placebo? 3)What are the side effects of Methylprednisolone in this patient population, and
how common are they? Participants in this study will be patients with PCS and cognitive
deficits, who will be asked to participate for 52 weeks. They will be randomly assigned to
one of two groups: One group will receive Methylprednisolone once daily for six weeks, with a
dosage reduction after week 4. The other group will receive a matching placebo once daily for
six weeks, following the same titration regimen to ensure blinding. Participants will attend
outpatient follow-up visits in weeks 8 and 20, with a final telephone follow-up after 52
weeks. Clinical examinations and safety monitoring will be conducted during the treatment
phase. This study's results may help develop more effective therapies for this condition.